|
Key Drug Pipeline Databases on Dialog
Lesson 3:
Pharmaprojects
(File 128/928)
• Objectives
• About Pharmaprojects
• Why Pharmaprojects?
• The Record
• Exercises
• Summary
• Glossary
• Print Tips
• About the Icons
Links to Other Lessons:
Technical Help
with Online Courses
Need Help?
E-mail the
|
|
|
|
Lesson 3: Pharmaprojects (File 128/928)
The Record (cont.)
Ric,
I see there are many ways to obtain specific licensing information, depending on the status and country you are interested in. This will prove very helpful.
Now I have a more scientific question.
I need therapeutic results as they relate to the mechanism of action. Any possibility of getting this?
Thanks,
Sharon
|
Keywords and corresponding codes are assigned to each Pharmaprojects record to indicate the therapeutic activity of the product described. This database also has a "linking" field to link the relevant pharmacological activity code and development status for each therapeutic category code assigned to a product profile. For example, if I want to find out what symptomatic antidiabetic (A10C) products are in phase I clinical trials specifically for diabetic neuropathies, I can use the linking field. Linking will ensure that the search does not include products in phase I for another therapeutic activity but which are in a lower stage of development for diabetic neuropathies. You also avoid missing data on products in phase I for diabetic neuropathies but launched for another indication.
We'll look first at the coding in this database
and then answer Sharon's question.
Pharmaprojects contains therapeutic class codes and pharmacological coding. I'll make sure to send this to Sharon too.
- Therapeutic Class Codes: Pharmaprojects bases its indexing on the use of the European Pharmaceutical Market Research Association (EPhMRA) anatomic/therapeutic classification scheme but with variations. Because Pharmaprojects has introduced a separate classification scheme for pharmacological action, it does not use EPhMRA codes that incorporate mechanism of action.
- Pharmacological Action: This field contains pharmacological classification, hierarchical for each drug with both primary and secondary activities being coded. The code is designed to locate mechanisms of action of pharmaceutical compounds.
- Indications: This field contains the disease or specific condition for which a drug is being developed. Indication can also be used as a linked field to link a particular indication with a particular status. For example you could use this to find all drugs that are in Phase II trials for breast cancer, regardless of the status they have reached for other indications.
View the record below to see the coding scheme for vatalanib. Then go to the next page.
ACTIVITY DATA
Therapy: Code Description
K6Z Anticancer, other
S1Z Ophthalmological
Rte of Admin: Code Description
A-PO Alimentary, po
Pharmacology: Code -- Description
KI-GFEN2-AN -- Endothelial growth factor receptor-2 kinase
inhibitor
KI-GFPL-AN -- Platelet-derived growth factor receptor kinase
inhibitor
KI-TY-KT-AN -- C-kit inhibitor
KI-GFEN1-AN -- Endothelial growth factor receptor-1 kinase
inhibitor
KI-GFEN3-AN -- Endothelial growth factor receptor-3 kinase
inhibitor
ANGG-AN -- Angiogenesis inhibitor
Therapy Pharmacology
Linking: Code Code1 Code2 Code3 Status
K6Z KI-GFEN2-AN KI-GFPL-AN KI-TY-KT-AN Phase III Clinical Trial
S1Z KI-GFEN2-AN ANGG-AN Phase II Clinical Trial
Indication: Description -- Status
Cancer, colorectal -- Phase III Clinical Trial
Cancer, renal -- Phase II Clinical Trial
Cancer, brain -- Phase II Clinical Trial
Cancer, breast -- Phase II Clinical Trial
Cancer, ovarian -- Phase II Clinical Trial
Cancer, pancreatic -- Phase II Clinical Trial
Cancer, prostate -- Phase II Clinical Trial
Cancer, lung, non-small cell -- Phase II Clinical Trial
Macular degeneration -- Phase II Clinical Trial
Target Data Codes:
3791: KDR
3791: FLK1
3791: VEGFR2
3791: VEGF receptor-2 tyrosine kinase
3791: VEGFR-2 tyrosine kinase
3791: vascular endothelial growth factor receptor 2
3791: CD309
5156: PDGFRA
5156: CD140a
5156: PDGFR2
5156: PDGFR kinase, bcr fusion-linked
5156: PDGFR/bcr fusion, PDGFR component
5156: PDGF receptor kinase, bcr fusion-linked
5156: platelet-derived growth factor receptor tyrosine
kinase, bcr fusion-linked
5156: PDGFR alpha
5156: PDGF receptor alpha
5156: MGC74795
5156: Rhe-PDGFRA
3815: KIT
3815: SCFR
3815: CD117
3815: SCF receptor
3815: stem cell factor receptor
3815: kit oncogene
3815: mast cell growth factor receptor
3815: c-kit receptor tyrosine kinase
3815: c-kit oncogene
3815: c-kit kinase
2321: FLT1
2321: FLT
2321: VEGFR1
2321: vascular endothelial growth factor receptor 1
2321: VEGF receptor-1 tyrosine kinase
2321: VEGFR-1 tyrosine kinase
2321: vascular permeability factor receptor 1
2324: FLT4
2324: PCL
2324: VEGFR3
2324: vascular endothelial growth factor receptor 3
2324: VEGF receptor-3 tyrosine kinase
2324: VEGFR-3 tyrosine kinase
2324: FLT41
Target Families:
3791: Enzyme > Kinase;
3791: Receptor;
5156: Enzyme > Kinase;
5156: Receptor;
3815: Enzyme > Kinase;
3815: Receptor;
2321: Enzyme > EC number > 2.7.10.1;
2321: Enzyme > Kinase;
2321: Receptor;
2324: Enzyme > EC number > 2.7.10.1;
2324: Enzyme > Kinase;
2324: Receptor.
PHARMACOKINETICS
Model (Dose)--Parameter--Values--Unit
Human--MTD--750--mg
|
Go to the next page.
3-5
|
|